The FDA is expected to allow compounding pharmacies to produce 14 injectable peptides, in a reversal from its previous ban on the substances, according to a New York Times report. The agency’s reversal on peptides, which are short amino acid chains, could open up the substances to a huge untapped market. For telehealth companies like Ro, Solace and Hims & Hers Health, whose ability to produce compound versions of these weight loss drugs created new business lines, peptides would be an obvious next move. More than 1 in 8 Americans is now taking GLP-1s.
Read the full article: The FDA’s U-Turn on Peptides Could Boost the Next Telehealth Boom //
Source: https://pitchbook.com/news/articles/the-fdas-u-turn-on-peptides-could-boost-the-next-telehealth-boom